Alzheimer Disease

Excellence Forums

Leaders in the field sharing authoritative insights and institutional best practices.
If approved, Biogen’s aducanumab would be the first FDA-approved drug for Alzheimer disease (AD) since 2003 and the first ever disease-modifying drug for AD. However, the development of aducanumab has been plagued by complexities and controversies which jeopardize its approval, writes Matthew Schrag, MD, PhD, from Vanderbilt University.
In this podcast, Erin Sundermann, PhD, discusses her research on sex-specific norms and cut points for verbal memory tests and how redefining the criteria for men vs women may improve diagnostic accuracy of amnestic mild cognitive impairment.